Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy
Stanford-Neuromodulationstherapie bei therapieresistenter Depression: randomisierte kontrollierte Studie zur Wirksamkeit, plus EEG-Studie zu Wirkmechanismus und potenziellem Biomarker
World Psychiatry · 2026-02 · 25 (1) · 105-116
DOI: 10.1002/wps.70032 ↗Auf einen Blick
Bei 48 Personen mit therapieresistenter Depression führte Stanford neuromodulation therapy häufiger zur Remission als Scheinbehandlung. EEG-Daten sprechen für eine Abnahme der frontalen Beta-Aktivität unter aktiver Stimulation.
Fragestellung
Wirkt Stanford neuromodulation therapy bei therapieresistenter Depression besser als Scheinbehandlung, und gibt es EEG-Hinweise zu Mechanismus und Biomarker?
Methode
Doppelblinde, sham-kontrollierte RCT mit 48 randomisierten Teilnehmenden; zusätzlich EEG-Auswertungen aus der initialen und der aktuellen Studie.
Ergebnisse
Remission nach 1 Monat: 50.0% unter aktiver vs. 20.8% unter Schein-Stimulation (p=0.035). Response: 54.2% vs. 25.0% (p=0.039). Beta-EEG nahm nur unter aktiver SNT ab.
Schlussfolgerung der Autor:innen
Die Studie repliziert die therapeutische Wirksamkeit von SNT, spricht für eine linksfrontale Beta-Suppression als möglichen Wirkmechanismus und nennt L-ACC-Beta-Aktivität als Kandidaten-Biomarker.
Kernaussagen
- Remission: 50.0% aktiv vs. 20.8% sham nach 1 Monat
- Response: 54.2% aktiv vs. 25.0% sham
- Linksfrontale Beta-Suppression und L-ACC-Beta als Biomarker-Kandidat
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift World Psychiatry, online erschienen am 14.01.2026. Verfasst von Ian H Kratter und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Themen: Depression
Abstract (Originalsprache)
Stanford neuromodulation therapy (SNT) is a rapid‐acting, high‐dose, intermittent theta‐burst stimulation protocol. Although it has previously demonstrated efficacy for treatment‐resistant depression (TRD) in a randomized controlled trial (RCT), replication in a larger sample is needed. Additionally, the electrophysiological effects of SNT remain unknown. Here we report results from a new double‐blind, sham‐controlled RCT along with electroencephalography (EEG) findings from the initial and current trials. In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT. At 1‐month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants (χ 2 1,48 =4.5, p=0.035), and response (secondary outcome) similarly favored active treatment (54.2% vs. 25.0%; χ 2 1,48 =4.3, p=0.039). Beta band EEG findings converged across trials: frontal beta power decreased significantly following active but not sham SNT in both the initial pilot study and the current trial. Additionally, beta baseline activity and post‐SNT changes related to treatment efficacy in the current study. Specifically, greater post‐SNT reduction in left anterior cingulate cortex (L‐ACC) beta power correlated with greater clinical improvement immediately (rho=0.48, p=0.019) and 1‐month after (rho=0.51, p=0.012) active SNT. Moreover, higher pre‐treatment L‐ACC beta power predicted greater subsequent clinical benefit from active SNT (immediate‐post: β=‐10.26, p=0.0042; 1‐month after: β=‐9.00, p=0.024). Neither of these L‐ACC beta power findings was observed with sham stimulation. In sum, this study replicates SNT’s therapeutic efficacy, identifies left frontal beta suppression as a potential mechanism of action, and highlights baseline L‐ACC beta power as a candidate scalable pre‐treatment biomarker of efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
- US Department of Veterans Affairs, Palo Alto, CA, USA.
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
- Baylor College of Medicine, Houston, TX, USA.
- Pôle Hospitalo-Universitaire de Psychiatrie Adulte, Centre Hospitalier G. Régnier, Rennes, France.
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.
Förderung
- NIMH NIH HHS
Zitieren
APA
Kratter, I. H., Austelle, C. W., Lissemore, J. I., Wada, M., Geoly, A., Chaiken, A., Kaloiani, I., Johnson, N., Wan, S., Kozyr, L., Makarewycz, E., Wong, B., Sridhar, M., Espil, F. M., Bassano, N., Kim, B., Ehrie, J., Maron-Katz, A., Tischler, C., …, & Williams, N. R. (2026). Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World Psychiatry, 25(1), 105-116. https://doi.org/10.1002/wps.70032
Vancouver
Kratter IH, Austelle CW, Lissemore JI, Wada M, Geoly A, Chaiken A, et al. Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World Psychiatry. 2026;25(1):105-116. doi:10.1002/wps.70032
BibTeX
@article{Kratter2026,
author = {Kratter, Ian H and Austelle, Christopher W and Lissemore, Jennifer I and Wada, Masataka and Geoly, Andrew and Chaiken, Anna and Kaloiani, Irakli and Johnson, Noriah and Wan, Stephanie and Kozyr, Lena and Makarewycz, Ethan and Wong, Brendan and Sridhar, Malvika and Espil, Flint M and Bassano, Nick and Kim, Bora and Ehrie, Jarrod and Maron-Katz, Adi and Tischler, Claudia and Nejad, Romina and Batail, Jean-Marie and Phillips, Angela L and Cole, Eleanor J and Ford, Tiffany J and Bentzley, Brandon S and Jo, Booil and Schatzberg, Alan F and Spiegel, David and Rolle, Cammie and Sahlem, Gregory L and Williams, Nolan R},
title = {Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy},
journal = {World Psychiatry},
year = {2026},
volume = {25},
number = {1},
pages = {105--116},
doi = {10.1002/wps.70032}
}
EUVIMED